MAAT PHARMA SACA (MAAT.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:MAAT - FR0012634822 - Common Stock
MAAT.PA Key Statistics, Chart & Performance
The current stock price of MAAT.PA is 4.195 EUR. In the past month the price increased by 9.53%. In the past year, price decreased by -46.63%.
MAAT.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 74.35 | 48.75B | ||
| ARGX.BR | ARGENX SE | 72.39 | 47.47B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 19.91B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.22B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.35B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.78B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.80B | ||
| 5CV.DE | CUREVAC NV | 5.06 | 991.20M | ||
| NANO.PA | NANOBIOTIX | N/A | 887.16M | ||
| PHIL.MI | PHILOGEN SPA | 20.61 | 687.14M | ||
| IVA.PA | INVENTIVA SA | N/A | 662.45M | ||
| 6IV.DE | INVENTIVA SA | N/A | 672.38M |
Related stock screener links
About MAAT.PA
Company Profile
Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 60 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.
Company Info
MAAT PHARMA SACA
70 Avenue Tony Garnier
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 63
Phone: 33428291400
MAAT PHARMA SACA / MAAT.PA FAQ
What does MAAT PHARMA SACA do?
Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 60 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.
Can you provide the latest stock price for MAAT PHARMA SACA?
The current stock price of MAAT.PA is 4.195 EUR. The price decreased by -0.83% in the last trading session.
Does MAAT stock pay dividends?
MAAT.PA does not pay a dividend.
How is the ChartMill rating for MAAT PHARMA SACA?
MAAT.PA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of MAAT stock?
MAAT PHARMA SACA (MAAT.PA) has a market capitalization of 78.66M EUR. This makes MAAT.PA a Micro Cap stock.
MAAT.PA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to MAAT.PA. When comparing the yearly performance of all stocks, MAAT.PA is a bad performer in the overall market: 92.04% of all stocks are doing better.
MAAT.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MAAT.PA. Both the profitability and financial health of MAAT.PA have multiple concerns.
MAAT.PA Financial Highlights
Over the last trailing twelve months MAAT.PA reported a non-GAAP Earnings per Share(EPS) of -2.15. The EPS decreased by -6.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -63.7% | ||
| ROE | -375.32% | ||
| Debt/Equity | 1.43 |
MAAT.PA Forecast & Estimates
12 analysts have analysed MAAT.PA and the average price target is 18.14 EUR. This implies a price increase of 332.45% is expected in the next year compared to the current price of 4.195.
For the next year, analysts expect an EPS growth of 11.78% and a revenue growth 162.46% for MAAT.PA